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Abstract 
 Cancer is a leading cause of mortality worldwide. Cancer arises due to a series of 
somatic mutations that accumulate within the nucleus of a cell which enable the cell to 
proliferate in an unregulated manner. These mutations arise as a result of both 
endogenous and exogenous factors. Genes that are commonly mutated in cancer cells are 
involved in cell cycle regulation, growth and proliferation. It is known that both nature 
and nurture play important roles in cancer development through complex gene-
environment interactions; however, the exact mechanism of these interactions in 
carcinogenesis is presently unclear. Key environmental factors that play a role in 
carcinogenesis include smoking, UV light and oncoviruses. Angiogenesis, inflammation 
and altered cell metabolism are important factors in carcinogenesis and are influenced by 
both genetic and environmental factors. Although the exact mechanism of nature-nurture 
interactions in solid tumour formation are not yet fully understood, it is evident that 
neither nature nor nurture can be considered in isolation. By understanding more about 
gene-environment interactions, it is possible that cancer mortality could be reduced.  
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Introduction  
Cancer is one of the leading causes of death worldwide. In 2012 there were a reported 8.2 
million deaths attributable to cancer [1]. Over the past half of a century, research has 
shown that cancer arises as a result of alterations to DNA. These somatic mutations 
provide a cell with attributes that enable it to bypass the regulatory mechanisms that 
control normal cell growth and proliferation. These traits – termed the “Hallmarks of 
Cancer” [2] – allow a cell to proliferate abnormally and confer the potential for growth at 
sites distant to the primary tumour. Key hallmarks include: sustained proliferation and 
immortality; evasion of apoptosis and growth suppression; genome instability; induction 
of angiogenesis and inflammation; invasion and metastasis [3]. “Cancer” is a broad term 
encompassing over 200 distinct diseases [4] which are unified by the common principle 
of uncontrolled cell growth and metastatic potential. However, cancers differ vastly in 
their aetiology. Some cancers share common mutations and risk factors; however, there 
are many cancers that would be better described as distant cousins than siblings. The 
broad variation in cancer aetiology has implications when trying to address the question 
“What causes cancer?” Sporadic mutations commonly arise and accumulate as a result of 
exposure to environmental carcinogens, whilst rare hereditary cancer syndromes often 
arise as a result of an inherited mutation with little to no environmental input [5]. It is 
widely accepted that the majority of cancers arise through a complex series of 
interactions between genes (“nature”) and the environment (“nurture”). Theses 
interactions vary between individuals, genders and ethnicities [6]. This variation explains 
why not everyone who is exposed to the same environmental factors will develop cancer. 
It is estimated that 95 % of cancers are explained by the environment interacting with 
genes with the remaining 5 % of cancers explained by genetics alone [7]. Whilst there are 
many known environmental and genetic factors which play a part in the development and 
progression of solid tumours (carcinogenesis), it is difficult to identify and quantity the 
role that each factor plays. This review focuses on the mechanism by which genetic and 
environmental factors contribute to carcinogenesis and explores the complex mechanisms 
of key gene-environment interactions.  
Models and Stages of Carcinogenesis  
Natural Selection  
During carcinogenesis, a cell acquires a series of genetic mutations. The process by 
which the mutated cell gives rise to cancer is frequently compared to Darwin’s theory of 
evolution, whereby cells with mutations which confer increased replicative and survival 
abilities are ‘selected’ to survive. Selected cells that acquire enough mutations so as to 
confer autonomy may go on to form malignant tumours. Additionally, cells that acquire a 
limited number of mutations may foster benign tumours. As the number of somatic 
mutations that a cell has acquired increases, the chance of tumour formation also 
increases. In some cell types that already show evidence of neoplasia (abnormal growth), 
the rate of acquisition of further mutations is increased. This increases the chance for an 
already-mutated cell to acquire the additional genetic alterations which are necessary for 
the formation of a solid tumour [8].  
Tumour Initiation and Promotion  
Tumour development and progression is known to be a stepwise process occurring over a 
variable period of time. The first steps in tumour development are initiation and 
promotion [9]. Initiation may occur spontaneously or be caused by an endogenous or 
exogenous mutagen (such as reactive oxygen species or tobacco smoke respectively) [10, 
11]. In the context of skin cancer, initiating agents include environmental chemical 
carcinogens and UV light [12]. Initiating agents cause damage to DNA and can therefore 
activate proto-oncogenes (such as KRAS) and inactivate tumour suppressor genes (TSGs), 
such as TP53. However, initiation will not give rise to a cancer on its own: a promoting 
agent is needed. A promoter is a compound which has little to no carcinogenic effect in 
isolation but has the ability to promote tumour growth when applied subsequent to an 
initiating factor [9]. When skin is repeatedly exposed to a promoter (such as UV light or 
certain chemicals), proliferation of the initiated cell is stimulated [12]. Promoting agents 
cause initiated cells to clonally expand without affecting neighbouring uninitiated cells 
[10]. The classic model used to identify the role of tumour initiators and promoters is the 
mouse skin model of chemical carcinogenesis. In this model, a single low dosage 
application of 7,12-dimethylbenz[a]-anthracene (DMBA; a component of tar) followed 
by treatment with the promoter 12-O-phorbol 12-myristate 13-acetate (TPA) leads to the 
formation of skin carcinomas. TPA interacts with Protein Kinase C (PKC) which 
activates the mitogen-activated protein kinase (MAPK) pathway. Activation of the 
MAPK pathway drives cell proliferation (see Fig.1) [10, 13]. The mouse skin model has 
since been used to study defects in genes and signaling pathways at different stages of 
tumour development. Tumour promotion is also driven by inflammatory cytokines. This 
mechanism was first demonstrated using mouse models of colon, skin and liver cancer. 
Cytokines activate transcription factors (such as STAT3, NF-º B and AP-1) which in turn 
promote transcription of key proliferation and survival genes (see Fig.1) [14].  
Tumour Progression and Metastasis  
Tumour progression and metastasis occurs as a result of further genetic alteration, such as 
changes in gene expression [12]. The ‘metastatic cascade’ refers to the process which 
results in cancer cells spreading from their primary location to a distant site. These steps 
include: proliferation, angiogenesis, detachment/local invasion, entry to and exit from 
circulation (intravasation and extravasation respectively) and growth at a distant site [15]. 
For a cell to invade locally and subsequently metastasise, it must first undergo alterations 
which give it a more invasive phenotype. These changes include upregulation of 
proteases (allowing the cell to invade through structures such as the extracellular matrix 
and the basement membrane) and downregulation of cell-to-cell adhesion molecules 
(allowing the cell a greater degree of motility) [16]. The relative infrequency of 
metastasis suggests that metastatic deposits arise from rare cells within the primary 
tumour which have the ability to successfully colonise distant sites within the human 
body. This concept is termed “metastatic inefficiency”. There are ongoing efforts by 
some groups to find genes specifically involved in metastasis. However, it has also been 
argued that these genes do not exist and that metastasis instead arises as the result of 
mutations in well-known TSGs and oncogenes. The heterogeneity between different 
cancers (and between the same cancer in different patients) means that both theories may 
be true. Indeed it is well known that there are many different paths that a cell can take to 
become a cancer [17].  
The Role of Nature in Carcinogenesis  
Somatic Mutations  
It is known that the somatic mutations that result in cancer formation arise due to damage 
by endogenous and exogenous factors. Mutations in a cancer cell are classified by the 
nature of the resulting DNA sequence change. These changes can be relatively small such 
as insertions, substitutions and deletions of a short segment of DNA or they can be larger 
changes, such as an increase or decrease in the number of chromosomes found in normal 
diploid cells. It should be noted that the majority of damage to DNA is repaired [8]. 
Somatic mutations within a cancer cell can be classified as either driver or passenger 
mutations. Driver mutations offer a selective growth advantage to a cell. Passenger 
mutations do not offer a growth advantage but were present in the cell at the time of 
acquisition of a driver mutation. It is thought that driver mutations represent only a small 
proportion of the total number of mutations within a cancer [18]. It is probable that most 
cancers possess more than one driver mutation and that this number will vary between 
different cancers. It has been suggested that 5–7 driver mutations are required for the 
formation of some solid tumours, such as breast, prostate and colorectal [8]. In non-small 
cell lung cancer, for example, several driver mutations have been identified including 
mutations in ALK, EGFR, HER2, BRAF, KRAS, MET, PIK3CA, MAP2K1 and AKT1 [19].  
  
 Fig. 1 Factors contributing to the acquisition of the hallmarks of cancer in a solid tumour cell. This 
schematic shows only some of the critical and complex interactions involved in carcinogenesis. Mutations 
in genes coding for key regulators of cell cycle, growth and proliferation (green stars) arise due to insult 
from both exogenous and endogenous sources. These mutations (genetic instability) are likely to work 
synergistically to produce a solid tumour. Tumour promoting inflammation plays a key part in tumour 
development and has a role in sustaining proliferation and in activating invasion and metastasis. STAT3, 
NF-º B and AP-1 are transcription factors found within tumour-associated macrophages (TAMs), the 
tumour microenvironment and the tumour cell itself which lead to the activation of IL-8 and VEGF. IL-8 
and VEGF are also activated by hypoxia and play key roles in inducing angiogenesis. (Me) = gene 
promoter methylation which can result in silencing of TSGs. (GF) = growth factor binding to its receptor 
and activating the MAPK pathway, resulting in cell proliferation. ROS = reactive oxygen species, shown 
here to be produced by mitochondria in the cytoplasm as part of normal cellular metabolism. 
(Deregulation of cellular energetics [Dereg. Cell Energetics] is also depicted, whereby the tumour cell 
switches from aerobic respiration in the mitochondria to anaerobic glycolysis within the cell cytoplasm. 
This metabolic alteration is thought to play a role in carcinogenesis)  
  
Cell Cycle  
The cell cycle is the series of steps that a cell must progress through in order to 
proliferate. It is tightly controlled by several important checkpoints. These checkpoints 
assess DNA damage, cell size and extracellular growth signals and ensure that damaged 
DNA is not passed on to prospective daughter cells. If an abnormality is detected, the cell 
will arrest at G1 or G2 checkpoints until the damage is repaired. Cyclins and cyclin-
dependent kinases (CDKs) are key regulators which govern progression through the cell 
cycle. Mutations in either cyclins or CDKs can allow a mutated cell (which should have 
arrested at a checkpoint) to continue through the cell cycle, leading to the formation of 
two daughters cells which also possess the damaged DNA [23]. This is a key step in solid 
tumour formation. The tumour suppressor protein p53 (known also as the “guardian of 
the genome”) is able to induce cell cycle arrest. p53 is also involved in the repair of 
DNA, senescence and apoptosis. Inactivation of p53 causes a loss of tumour suppression 
activity within a cell, as well as a gain of survival and growth abilities as is seen in many 
cancers. Unchecked progression through checkpoints and evasion of anti-growth signals 
lead to genomic instability and contributes to the probability of metastasis [24]. Usually 
both alleles of a TSG have to be altered before a functional effect is seen (a recessive loss 
of function). The mechanism by which a TSG (such as RB1) suffers a recessive loss of 
function due to mutations in both alleles of the gene is termed the “Knudson two-hit 
hypothesis” [25]. TP53 (the gene coding for p53) is an important exception to the two-hit 
hypothesis: a mutation in only one allele of the gene is needed for a loss of function of 
the normal p53 protein. Thus p53 mutations have the ability to act in a dominant negative 
manner. Oncogenes (such as Ras) need only one allele to be affected for an abnormal 
effect to be observed (a dominant gain of function) [2]. Oncogenes become activated 
when proto- oncogenes are altered in one of three ways, namely mutation, gene 
amplification or chromosomal rearrangement. Proto-oncogenes code for proteins which 
are involved in normal cell growth, differentiation and survival. Activation of oncogenes 
often leads to the production of a mutant protein with increased, unregulated activity 
[26].  
The Role of Nurture in Carcinogenesis  
Environmental Factors in Tumour Development and Progression  
In a medical context, environmental exposures include all non-genetic exposures such as 
diet, lifestyle and infections [27]. Since Sir Percivall Pott first realised that environmental 
carcinogens could cause cancer in the 18th century (chimney soot vis-à-vis squamous cell 
carcinoma of the scrotum), many other environmental factors have been found to play a 
role in cancer development. These exogenous factors cause genetic alterations in addition 
to the changes that occur spontaneously within the cell. Known environmental mutagens 
include asbestos, arsenic and radon [27]. Environmental factors are known to play a role 
in early cancer development by causing alterations to the genome which give rise to a 
pre-malignant lesion [28]. The roles of environmental factors in later stages of 
carcinogenesis are less well described; however, there are certain environmental factors 
which are likely to play a role throughout tumour development and progression. Until 
recently, the role of environmental agents in epigenetic change was unknown (it was 
thought that these agents acted exclusively by direct genomic alteration). However, it is 
now known that external agents can cause epigenetic alterations (especially gene 
promoter methylation). Epigenetic changes are functional changes to the genome of a 
cell, which may result in altered gene expression, without altering the primary DNA 
sequence itself. Gene promoter methylation can frequently lead to silencing of the 
affected gene. Tumour-promoting inflammation (such as that caused by cigarette smoke) 
can also cause epigenetic changes which lead to tumour initiation (see Fig.2) [14]. 
Certain dietary factors and obesity are also known to cause inflammation and have been 
implicated in carcinogenesis. Whilst much effort has gone in to finding genetic and 
environmental risk factors, there may also be a clinical benefit in identifying factors that 
are protective against cancer.  
Cigarette Smoke  
Smoking and lung cancer is perhaps the best-known example of the role of an 
environmental factor in carcinogenesis. Sir Richard Doll first proved this link in 1950 and 
since then much has become known about the diverse role of cigarette smoke in lung 
cancer [29]. Smoking has also been linked to a variety of other cancers (see Table 1). 
Smoking plays a direct role in carcinogenesis through the activation of oncogenes and the 
inactivation of proto-oncogenes. Smoking also indirectly contributes to carcinogenesis 
through impaired mucociliary clearance; activation of macrophages; increased levels of 
proteases and dampening of the immune system. Cigarette smoke is known to contain a 
multitude of toxic and carcinogenic compounds including carbon monoxide, hydrogen 
cyanide, ammonia and vinyl chloride [30]. Cigarette smoke also contributes to tumour 
promoting inflammation and can cause epigenetic changes to the genome (see Fig.2) 
[14].  
UV Exposure  
Intense ultraviolet (UV) light exposure has been implicated in the development of 
melanoma. UV light damage has recently been shown to account for as many as 46 % of 
all driver mutations in melanoma. As with cigarette smoke, the mechanistic role of UV 
light in cancer development is broad and includes the generation of reactive oxygen 
species (ROS) [31]. However, UV exposure has also been shown to play a nonmutagenic 
role in melanoma development through the activation of tumour-driving cell signaling 
pathways. Despite the evidence linking UV exposure and melanoma, the exact 
mechanisms behind this link remain unclear: the common genetic changes that result in 
NRAS and BRAF driver mutations in melanoma are not the C to T base transitions which 
are typical of UVB damage [32]. As with other environmental factors, it is likely that UV 
exposure plays a diverse role in carcinogenesis, such as in initiation and promotion [12].  
Viruses  
Over the past half a century, much has been discovered about the role of viruses in cancer 
and several cancer-causing viruses (oncoviruses) have now been identified. These viruses 
are known to play a role in the development and progression of human tumours. 
Oncoviruses are diverse in their mechanism of action and include retroviruses (human T-
lymphotropic virus-I), RNA viruses (hepatitis C virus) and multiple subtypes of DNA 
viruses (which include Epstein-Barr virus and Human papillomavirus) [33]. HIV is also 
implicated in the development of some cancers (such as Kaposi’s sarcoma) through 
induction of immunosuppression; however, the virus does not directly cause tumour 
growth [34]. In addition to viruses, parasites and bacteria are also known to cause cancer 
(for example, inflammation in the stomach due to Helicobacter pylori colonisation is the 
greatest risk factor for developing gastric cancer [35]). These infectious agents (viruses, 
parasites and bacteria) can be classified as either direct carcinogens (viral oncogenes 
expressed) or indirect carcinogens (cause mutations through chronic inflammation); 
however, some viruses do not fit exactly into either description and are likely to have 
multiple roles and interactions in cancer development [33]. There are other known 
environmental exposures (such as dietary aflatoxin and smoking) which act as cofactors 
in the induction of certain viral cancers (see Fig.2) [34].  
  
Solid Tumour Nature Risk Factors Nurture Risk Factors 
Bladder Cancer Mutations in: PRKDC, TP53, 
ARID1A  
Smoking, dyes 
Breast Adenocarcinoma Mutations in: BRCA1, BRCA2, 
TP53, PIK3CA, MAP3K1, HER2; 
oestrogen 
Obesity, hormone replacement 
therapy, late menarche, having 
more children, radiation, 
alcohol 
Colorectal Cancer (CRC) Mutations in: KRAS, NRAS, APC, 
PRKDC, Wnt/² -catenin signaling; 
inflammatory bowel disease 
(IBD)*; 
genetic syndromes namely 
hereditary nonpolyposis CRC 
(HNPCC) and familial 
adenomatous polyposis (FAP) 
Smoking, alcohol, low fibre, 
obesity, H. pylori, 
inflammatory bowel disease 
(IBD)*, obesity, red meat  
Non-Small Cell Lung 
Cancer (NSCLC)  
Mutations in: KRAS, NRAS, TP53 
ALK, EGFR, HER2, BRAF, 
KRAS, MET, PIK3CA, MAP2K1, 
AKT1 
Smoking, air pollution, radon21 
von Hippel-Lindau 
Syndrome (syndrome 
results in 
haemangioblastomas, 
clear cell renal 
carcinomas and 
phaeochromocytoma) 
Germline mutation of the von 
Hippel-Lindau TSG on 
chromosome 3p25  
  
Environmental factors not a 
recognised cause of this disease 
Endometrial Carcinoma Mutations in: KRAS, NRAS, 
PIK3CA, PIK3R1, ARID1A; 
oestrogen 
Obesity, diabetes 
Table 1 Key risk factors associated with development of some solid tumours. This table demonstrates 
some of the key genetic and environmental risk factors for the development of some cancers. The 
mutations listed include DNA repair genes (BRCA1, BRCA2, TP53) and genes involved in cell growth 
and proliferation (KRAS, NRAS, PIK3CA, MAP3K1, MAP2K1 HER2). Note that this table is not 
exhaustive and there are likely to be many cancer-causing factors which are unknown at present. 
*IBD itself is a disease which is caused by gene-environment interactions. [20–22]  
 
Fig.2 Environmental factors involved in the development of some cancers. There are many environmental 
factors that play a role in the development of cancer. As well as directly damaging DNA (green stars), 
environmental factors work synergistically with each other to cause mutations. Some of these interactions 
are shown above; however, this figure is not complete: these interactions are infinite and are potentially 
bi-directional. Not all of the exposures shown above are needed for cancer development. (Me) = gene 
promoter methylation which can result in silencing of TSGs  
  
Nature and Nurture in Key Hallmarks of Cancer  
Inflammation  
Inflammation is a key hallmark of cancer [3] and both environmental and genetic factors 
have been shown to play a role tumour-promoting inflammation. An inflammatory 
tumour microenvironment (TME) is necessary for the development and progression of all 
solid tumours, and immune and inflammatory cells are often seen within tumours. 
Tumour-associated macrophages (TAMs) and T cells are amongst the most common 
immune cells found in the TME. These cells produce various inflammatory mediators 
including cytokines, chemokines and growth factors. These inflammatory components 
play a role in neoangiogenesis, tumour invasion and metastasis and in causing further 
damage to DNA. It is also thought that inflammation may play a direct role in 
mutagenesis [14].  
Angiogenesis  
At some stage in tumour development, a tumour will ‘outgrow’ its blood supply resulting 
in hypoxia and necrosis at the core of the tumour. These conditions drive the ‘angiogenic 
switch’ (the upregulation of proangiogenic factors and the downregulation of 
antiangiogenic factors). This change promotes new blood vessel formation 
(neoangionesis) and increases the likelihood of tumour metastasis [36]. Vascular 
endothelial growth factor (VEGF) is the primary mediator of angiogenesis [37]. These 
agents recruit TAMs to the site of necrosis where they produce both inflammatory and 
angiogenic mediators. Genes which promote angiogenesis (such as IL-8 and VEGF) are 
turned on by transcription factors produced by TAMS (such as AP-1, STAT3 and NF-
º B)(see Fig.1) [14]. Low concentration cigarette smoke extract has been shown to cause 
the release of the pro-inflammatory cytokines IL-8 and TNF-± through activation of NF-
º B and the generation of reactive oxygen species [38]. It has been shown that NF-º B is a 
key component of inflammation-induced growth and progression [39]. Activation of NF-
º B in inflammatory cells causes production of inflammatory mediators. These mediators 
cause NF-º B to recruit more inflammatory cells in a feed-forward loop [14]. 
Additionally, TNF-± [40] and IL-8 [41] have been shown to play a role in all stages of 
cancer growth. Cigarette smoke is also known to cause production of other inflammatory 
cytokines. It is likely that these inflammatory mediators will also play roles in tumour 
development, progression and angiogenesis.  
  
Altered Cell Metabolism  
In addition to unregulated proliferation, energy metabolism within a cancer cell also 
becomes aberrant at some stage during carcinogenesis. The “Warburg effect” is the 
process by which a cancer cell switches from aerobic respiration to anaerobic glycolysis. 
The exact survival benefit of this switch remains unclear given the inefficiency of 
glycolysis compared to aerobic respiration; however, it is thought that glycolysis plays a 
role in promoting cell proliferation [3]. As well as variation in environmental exposures, 
individuals vary also in their ability to metabolise and excrete potentially mutagenic 
agents. This variability is due to the existence of polymorphisms in genes coding for 
enzymes that are involved in key metabolic functions. Individuals with variants of 
enzymes which are less well able to clear damaging factors may be more likely to suffer 
DNA damage. These enzymes include the cytochrome P450 family which are based in 
the mitochondria and in the endoplasmic reticulum [5]. Variants in DNA repair enzymes 
have also been found to exist and to be associated with an elevated risk of some cancers 
[42]. These variants once again demonstrate the infinite variation and complexity of 
gene-environment interactions in cancer.  
 
Challenges and Future Perspectives  
Unraveling the Complexities of Nature-Nurture Interactions  
Both genetics and the environment play key roles in solid tumour development and 
progression. The presence of gene-environment interactions in cancer has been well 
documented in the literature; however, the exact mechanism of these interactions remains 
elusive. It is clear that the interactions are extremely complex and that the role of both 
components cannot be considered in isolation. It is known that even human behaviours 
that lead to environ- mental exposures (such as smoking) are likely to be influenced by 
genetics. It can therefore be seen that gene- environment interactions are ‘bi-directional’: 
genetics pre- dispose an individual to an exposure and the exposure causes disease in the 
genetically predisposed individual. The possibility of ever fully understanding the 
mechanisms of gene-environment interactions is unknown. It is also unclear whether 
unraveling these exact mechanisms will result in a clinical benefit [43]. However, a 
survival benefit has already been gained from merely identifying such interactions. Since 
Doll first linked smoking to lung cancer in 1950 [29], public health campaigns have 
raised awareness of the health risks associated with smoking and have reduced cancer 
related deaths. By understanding more about gene-environment interactions, it is possible 
that we would be able to develop new screening tests for cancers based on known risk 
factors which could lead to a reduction in cancer mortality worldwide [43].  
 
 
Looking ahead  
Ultimately, neither nature nor nurture can be considered in isolation in carcinogenesis. 
Quantifying environmental exposures is difficult and wrought with inaccuracies. There is 
now a need for large gene-environment studies that are able to demonstrate the 
relationship between gene variants and environmental exposures in cancer. Indeed, 
perhaps it is time to toss out the old paradigm of “nature versus nurture” and replace it 
with a new one: “nature and nurture”.  
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